Title: Effectiveness and Safety of Tofacitinib in the Management of Ulcerative Colitis: A
Brazilian Observational Multicentric Study.
Version: 1 Date: 04 Dec 2024
Reviewer:  Ulf Helwig
Reviewer's report:
Dear Authors,
Congratulations to this important real-world study.
You have discussed excellent the  limitations of a retrospective study.
I would recommend to make a comment on the  disproportion of 1year results regarding bio-
naive and bio exposed cohort. Why is the clinical remission different as we  know from other
studies but not the endoscopic response/ mucosal healing?
Regards
Title: Effectiveness and Safety of Tofacitinib in the Management of Ulcerative Colitis: A
Brazilian Observational Multicentric Study.
Version: 1 Date: 04 Dec 2024
Reviewer:  Ulf Helwig
Reviewer's report:
Dear Authors,
Congratulations to this important real-world study.
You have discussed excellent the  limitations of a retrospective study.
I would recommend to make a comment on the  disproportion of 1year results regarding bio-
naive and bio exposed cohort. Why is the clinical remission different as we  know from other
studies but not the endoscopic response/ mucosal healing?
Regards
Please review this paper.
user
Title: Effectiveness and Safety of Tofacitinib in the Management of Ulcerative Colitis: A
Brazilian Observational Multicentric Study.
Version: 1 Date: 04 Dec 2024
Reviewer:  Ulf Helwig
Reviewer's report:
Dear Authors,
Congratulations to this important real-world study.
You have discussed excellent the  limitations of a retrospective study.
I would recommend to make a comment on the  disproportion of 1year results regarding bio-
naive and bio exposed cohort. Why is the clinical remission different as we  know from other
studies but not the endoscopic response/ mucosal healing?
Regards
assistant